Abstract
The past decade has seen remarkable progress in our understanding of the scale of the global typhoid fever problem,1 the alarming emergence in south Asia of extensively drug-resistant Salmonella enterica serovar Typhi (S Typhi) threatening effective treatment,2 and the WHO prequalification of a typhoid conjugate vaccine,3 a new tool to prevent disease. In The Lancet, Firdausi Qadri and colleagues report the analysis to 18 months of follow-up of a cluster-randomised trial of the WHO prequalified S Typhi Vi polysaccharide tetanus toxoid conjugate vaccine (Vi-TT; Tybar TCV, Bharat Biotech International, Hyderabad, India) among infants and children aged 9 months to younger than 16 years in the densely populated and highly mobile urban area of Mirpur, Dhaka, Bangladesh.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
